Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmedetomidine for hemodynamic stability and sedation after coronary artery bypass surgery in opium-addicted patients
IRCT20230825059256N1Phase 3Completed
- Sponsor
- Kerman University of Medical Sciences
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of dexmedetomidine in coronary arteriosclerosis and opioid use disorder (OUD), sponsored by Kerman University of Medical Sciences. Primary endpoints: Hemodynamic changes and Sedation after heart surgery. Started Sep 2023; status: completed.
02
Drugs
dexmedetomidine
03
Conditions
coronary arteriosclerosisopioid use disorder (OUD)
Beyond the preview
Go deeper on IRCT20230825059256N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20230825059256N1.